BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
Stocks · News reference
Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — NEKTAR THERAPEUTICS (NKTR)
Filed: 2026-09-08 AccNo: 0001213900-26-098042 Size: 187 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Atopic Dermatitis
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2wFirst large, placebo-controlled trial to support T-reg modulation as